Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials.


Journal

Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 8 8 2020
medline: 20 3 2021
entrez: 8 8 2020
Statut: ppublish

Résumé

Gender disparities in authorship of heart failure (HF) guideline citations and clinical trials have not been examined. We identified authors of publications referenced in Class I Recommendations in United States (n=173) and European (n=100) HF guidelines and of publications of all HF trials with >400 participants (n=118) published between 2001 and 2016. Authors' genders were determined, and changes in authorship patterns over time were evaluated with linear regression and nonparametric testing. The median proportion of women authors per publication was 20% (interquartile range [IQR], 8%-33%) in United States guidelines, 14% (IQR, 2%-20%) in European guidelines, and 11% (IQR, 4%-20%) in HF trials. The proportion of women authors increased modestly over time in United States and European guidelines' references (β=0.005 and 0.003, respectively, from 1986 to 2016; In HF practice guidelines and trials, few women are authors of pivotal publications. Higher number of women authors is associated with higher enrollment of women in HF trials. Barriers to authorship and representation of women in HF guidelines and HF trial leadership need to be addressed.

Sections du résumé

BACKGROUND
Gender disparities in authorship of heart failure (HF) guideline citations and clinical trials have not been examined.
METHODS
We identified authors of publications referenced in Class I Recommendations in United States (n=173) and European (n=100) HF guidelines and of publications of all HF trials with >400 participants (n=118) published between 2001 and 2016. Authors' genders were determined, and changes in authorship patterns over time were evaluated with linear regression and nonparametric testing.
RESULTS
The median proportion of women authors per publication was 20% (interquartile range [IQR], 8%-33%) in United States guidelines, 14% (IQR, 2%-20%) in European guidelines, and 11% (IQR, 4%-20%) in HF trials. The proportion of women authors increased modestly over time in United States and European guidelines' references (β=0.005 and 0.003, respectively, from 1986 to 2016;
CONCLUSIONS
In HF practice guidelines and trials, few women are authors of pivotal publications. Higher number of women authors is associated with higher enrollment of women in HF trials. Barriers to authorship and representation of women in HF guidelines and HF trial leadership need to be addressed.

Identifiants

pubmed: 32757645
doi: 10.1161/CIRCHEARTFAILURE.119.006605
pmc: PMC7719050
mid: NIHMS1649015
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e006605

Subventions

Organisme : FDA HHS
ID : R18 FD006920
Pays : United States
Organisme : NHGRI NIH HHS
ID : T32 HG009495
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002541
Pays : United States

Références

J Am Coll Cardiol. 2018 Nov 27;72(21):2663-2667
pubmed: 30466523
JAMA Cardiol. 2018 Aug 1;3(8):682-691
pubmed: 29847674
JAMA Intern Med. 2019 May 28;:
pubmed: 31135815
Eur Heart J. 1999 Sep;20(17):1276-84
pubmed: 10454979
Circulation. 2017 Feb 7;135(6):506-517
pubmed: 28153987
J Investig Med. 2007 May;55(4):174-80
pubmed: 17651671
J Am Coll Cardiol. 2017 Sep 19;70(12):1525-1529
pubmed: 28911516
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
J Am Coll Cardiol. 2018 Jan 30;71(4):443-453
pubmed: 29389362
Lancet. 2019 Feb 9;393(10171):531-540
pubmed: 30739688
Heart. 2005 Mar;91(3):275-6
pubmed: 15710696
Circulation. 2019 Feb 19;139(8):1127-1129
pubmed: 30779644
Trends Pharmacol Sci. 2014 Aug;35(8):371-3
pubmed: 25086743
Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135-42
pubmed: 20160159
Circ Heart Fail. 2019 Jul;12(7):e006025
pubmed: 31296095
Lancet. 2019 Feb 9;393(10171):550-559
pubmed: 30739690
Nature. 1997 May 22;387(6631):341-3
pubmed: 9163412
Acad Med. 1995 Dec;70(12):1108-16
pubmed: 7495456
Am J Cardiol. 2017 Dec 1;120(11):2100-2109
pubmed: 28964383
BMC Womens Health. 2015 Oct 26;15:94
pubmed: 26503700
World Neurosurg. 2019 Oct;130:516-522.e1
pubmed: 31254703
Heart. 2005 Mar;91(3):283-9
pubmed: 15710701
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
JAMA. 2015 Sep 15;314(11):1149-58
pubmed: 26372584
Circulation. 2018 Jul 31;138(5):451-454
pubmed: 29789303
Circ Heart Fail. 2019 Jul;12(7):e005754
pubmed: 31296097
Lancet. 2018 Nov 17;392(10160):2152-2153
pubmed: 30496087
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e005040
pubmed: 30562072
Arch Intern Med. 2007 May 14;167(9):905-12
pubmed: 17502531
Circulation. 2018 Feb 20;137(8):880-882
pubmed: 29459476
JACC Heart Fail. 2019 Mar;7(3):267-271
pubmed: 30819383
J Am Coll Cardiol. 2018 May 8;71(18):1960-1969
pubmed: 29724348
J Am Coll Cardiol. 2018 Aug 7;72(6):681-685
pubmed: 30071998
JAMA Cardiol. 2018 Oct 1;3(10):1011-1019
pubmed: 30140928

Auteurs

Nosheen Reza (N)

Division of Cardiovascular Medicine (N.R.), Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

Ayman Samman Tahhan (AS)

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.S.T., A.A., A.H.H.).

Nadim Mahmud (N)

Division of Gastroenterology (N.M.), Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

Ersilia M DeFilippis (EM)

Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York City, NY (E.M.D.).

Alaaeddin Alrohaibani (A)

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.S.T., A.A., A.H.H.).

Muthiah Vaduganathan (M)

Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA (M.V.).

Stephen J Greene (SJ)

Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC (S.J.G., C.O., M.F.).

Annie Hang Ho (AH)

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA (A.S.T., A.A., A.H.H.).

Gregg C Fonarow (GC)

Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.).

Javed Butler (J)

Department of Medicine, University of Mississippi, Jackson (J.B.).

Christopher O'Connor (C)

Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC (S.J.G., C.O., M.F.).
Inova Heart and Vascular Institute, Falls Church, VA (C.O.).

Mona Fiuzat (M)

Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC (S.J.G., C.O., M.F.).

Orly Vardeny (O)

Minneapolis Veterans Affairs Health Care System and the University of Minnesota (O.V.).

Ileana L Piña (IL)

Wayne State University, Detroit, MI (I.L.P.).

JoAnn Lindenfeld (J)

Vanderbilt Heart and Vascular Institute, Nashville, TN (J.L.).

Mariell Jessup (M)

American Heart Association, Dallas, TX (M.J.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH